Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multicenter, Open Label, Two-part Study (Single Ascending Dose [Part 1], and Dose Expansion [Part 2]) to Evaluate Safety, Tolerability and Efficacy of PS-002, a Gene Therapy for the Treatment of Adult Participants With Primary IgA Nephropathy

Next Previous
Trial Profile

A Phase 1/2 Multicenter, Open Label, Two-part Study (Single Ascending Dose [Part 1], and Dose Expansion [Part 2]) to Evaluate Safety, Tolerability and Efficacy of PS-002, a Gene Therapy for the Treatment of Adult Participants With Primary IgA Nephropathy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PS 002 (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; First in man

Most Recent Events

  • 28 Nov 2025 Planned initiation date (estimated date of first patient enrollment) changed from 1 Oct 2025 to 1 Nov 2025.
  • 28 Nov 2025 Status changed from not yet recruiting to recruiting.
  • 04 Nov 2025 According to a Purespring Therapeutics media release, the company announced that new information to be presented on the study design and methodology of Puresprings Phase I/II study at the American Society of Nephrology (ASN) Kidney Week 2025, held from November 7, 2025, in Houston, Texas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top